Shopping Cart 0
Cart Subtotal
USD 0

Memorial Sloan Kettering Cancer Center - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Memorial Sloan Kettering Cancer Center (MSKCC) is a healthcare service provider that offers cancer treatment, cancer research and cancer education programs. The center conducts research in therapeutic areas of bone and marrow stem cell transplantation, cancer pathology, cancer therapeutics and drug development, cell biology, cell cycle regulation, cell death, cell signaling, immunology, genetics and genomics, molecular imaging and tumor growth. It provides diagnosis and treatment for cancer diseases such as adrenal tumors, AIDS-associated cancers, basal cell carcinoma, benign blood disorders, bladder cancer, bone cancer, brain tumors and breast cancer among others. The center also offers predoctoral and postdoctoral training. MSKCC is headquartered in New York, the US.

Memorial Sloan Kettering Cancer Center-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Memorial Sloan Kettering Cancer Center, Medical Devices Deals, 2012 to YTD 2018 11

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deal Details 16

Venture Financing 16

ORIC Pharma Raises USD50 Million in Series C Financing 16

Partnerships 18

Context Therapeutics Enters into Research Collaborations for Apristor 18

Immunomedics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 20

Bridge Medicines Enters into Agreement with Memorial Sloan Kettering Cancer Center 21

BlueRock Therapeutics Enters into Research Partnership with Memorial Sloan Kettering Cancer Center 22

Telix Pharma Enters into Agreement with Memorial Sloan Kettering Cancer 23

Daiichi Sankyo and Puma Biotech Enter into Research Agreement with Memorial Sloan Kettering Cancer Center 24

PathoQuest Enters into Agreement with Memorial Sloan Kettering 25

OSE Immunotherapeutics Enters into Partnership with Memorial Sloan Kettering Cancer Center 26

Royal Philips and Memorial Sloan Kettering Cancer Center Enter into Research Agreement 27

MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 28

Aprea Therapeutics Enters into Research Partnership with Memorial Sloan Kettering Cancer Center 29

Avacta Group Enters into Agreement with Memorial Sloan Kettering Cancer Center 30

Multiple Myeloma Research Foundation Enters into Agreement with Memorial Sloan Kettering Cancer Center 31

Seres Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 32

Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 33

Genocea Biosciences Enters into Agreement with Memorial Sloan Kettering Cancer Center 34

Advaxis Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 35

Cesca Therapeutics Enters into Agreement with Memorial Sloan Kettering Cancer Center 36

Peregrine Pharma Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 37

MabVax Therapeutics Enters into Co-development Agreement with Memorial Sloan Kettering Cancer Center 38

Sutro Biopharma Enters Into Co-Development Agreement With Memorial Sloan-Kettering Cancer Center 39

Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute Form Joint Venture 40

Licensing Agreements 41

Y-mAbs Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering 41

Immune-Onc Therapeutics Enters into Licensing Agreement with Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center 42

Abpro Enters into Licensing Agreement with Memorial Sloan Kettering Cancer 43

Lin Bioscience Enters into Licensing Agreement with Columbia University and Memorial Sloan Kettering Cancer Center 44

Fate Therapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 45

Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 47

Gritstone Oncology Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 48

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 49

Y-mAbs Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 50

Atara Biotherapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 51

Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 53

Sellas Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center for Vaccine to Target WT1 for Cancer 55

Eureka Therapeutics And Memorial Sloan-Kettering Cancer Center Enter Into Licensing Agreement With Novartis 56

Jounce Therapeutics Amends Licensing Agreement for JTX-2011 58

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 60

Memorial Sloan Kettering Cancer Center-Key Competitors 61

Memorial Sloan Kettering Cancer Center-Key Employees 62

Memorial Sloan Kettering Cancer Center-Locations And Subsidiaries 63

Head Office 63

Other Locations & Subsidiaries 63

Joint Venture 64

Recent Developments 65

Government and Public Interest 65

Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 65

Jun 26, 2018: Pancreatic Cancer Action Network Funds Innovative Scientists through Research Grants Program 66

May 02, 2018: St. Baldrick's Foundation Supports Innovative Childhood Cancer Research Through One-of-a-Kind Grant 67

Mar 21, 2018: Leukemia Patient's Legacy Helps Drive Innovative Cancer Clinical Trial 68

Feb 02, 2018: BCRF Announces Expansion of the Drug Research Collaborative 70

Feb 01, 2018: Fusions in Solid Tumours 71

Dec 14, 2017: Cancer Immunotherapy May Work Better in Patients with Specific Genes 72

Nov 14, 2017: St. Baldrick's Foundation Announces USD 2.2 Million in Grants to Give More Kids Access to Clinical Trials 73

Nov 02, 2017: Lung Cancer Research Foundation Awards USD 1.6 Million in Research Grants 74

Nov 02, 2017: New System for Treating Colorectal Cancer Can Lead to Complete Cure 76

Nov 01, 2017: CVS Health Foundation Awards USD 1 Million Dollars in Grants to Eight Cancer Centers to Increase Smoking Cessation Resources in the Oncology Setting 77

Sep 21, 2017: Grant funds chemotherapy-free breast cancer therapy research 78

Jun 01, 2017: The T.J. Martell Foundation Announces New Appointments to Board of Directors and USD 1.3M in Cancer Research Grants 79

Other Significant Developments 80

May 14, 2018: New Tool Helps People with Leukemia Better Understand Their Treatment Options 80

Appendix 81

Methodology 81

About GlobalData 81

Contact Us 81

Disclaimer 81


List Of Figure

List of Figures

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Memorial Sloan Kettering Cancer Center, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Memorial Sloan Kettering Cancer Center, Deals By Therapy Area, 2012 to YTD 2018 10

Memorial Sloan Kettering Cancer Center, Medical Devices Deals, 2012 to YTD 2018 11

Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

ORIC Pharma Raises USD50 Million in Series C Financing 16

Context Therapeutics Enters into Research Collaborations for Apristor 18

Immunomedics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 20

Bridge Medicines Enters into Agreement with Memorial Sloan Kettering Cancer Center 21

BlueRock Therapeutics Enters into Research Partnership with Memorial Sloan Kettering Cancer Center 22

Telix Pharma Enters into Agreement with Memorial Sloan Kettering Cancer 23

Daiichi Sankyo and Puma Biotech Enter into Research Agreement with Memorial Sloan Kettering Cancer Center 24

PathoQuest Enters into Agreement with Memorial Sloan Kettering 25

OSE Immunotherapeutics Enters into Partnership with Memorial Sloan Kettering Cancer Center 26

Royal Philips and Memorial Sloan Kettering Cancer Center Enter into Research Agreement 27

MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 28

Aprea Therapeutics Enters into Research Partnership with Memorial Sloan Kettering Cancer Center 29

Avacta Group Enters into Agreement with Memorial Sloan Kettering Cancer Center 30

Multiple Myeloma Research Foundation Enters into Agreement with Memorial Sloan Kettering Cancer Center 31

Seres Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 32

Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 33

Genocea Biosciences Enters into Agreement with Memorial Sloan Kettering Cancer Center 34

Advaxis Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 35

Cesca Therapeutics Enters into Agreement with Memorial Sloan Kettering Cancer Center 36

Peregrine Pharma Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 37

MabVax Therapeutics Enters into Co-development Agreement with Memorial Sloan Kettering Cancer Center 38

Sutro Biopharma Enters Into Co-Development Agreement With Memorial Sloan-Kettering Cancer Center 39

Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute Form Joint Venture 40

Y-mAbs Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering 41

Immune-Onc Therapeutics Enters into Licensing Agreement with Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center 42

Abpro Enters into Licensing Agreement with Memorial Sloan Kettering Cancer 43

Lin Bioscience Enters into Licensing Agreement with Columbia University and Memorial Sloan Kettering Cancer Center 44

Fate Therapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 45

Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 47

Gritstone Oncology Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 48

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 49

Y-mAbs Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 50

Atara Biotherapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 51

Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 53

Sellas Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center for Vaccine to Target WT1 for Cancer 55

Eureka Therapeutics And Memorial Sloan-Kettering Cancer Center Enter Into Licensing Agreement With Novartis 56

Jounce Therapeutics Amends Licensing Agreement for JTX-2011 58

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 60

Memorial Sloan Kettering Cancer Center, Key Competitors 61

Memorial Sloan Kettering Cancer Center, Key Employees 62

Memorial Sloan Kettering Cancer Center, Other Locations 63

Memorial Sloan Kettering Cancer Center, Subsidiaries 63

Memorial Sloan Kettering Cancer Center, Joint Venture 64

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Memorial Sloan Kettering Cancer Center, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.